Figure 5

Sensitivity and specificity of ΔT ₁ for everolimus and patupilone chemotherapy in the RIF-1 tumour model. A. C3H mice bearing RIF-1 tumours were treated with everolimus (10 mg/kg/day) or vehicle for 5 days and TVol and the spin–lattice relaxation of protons (T₁) in tumours was measured on day 0 and at the endpoint day 5 (n = 15 per group on day 0). In the everolimus group, one mouse died before endpoint and T₁ measurement failed in another mouse on day 5. Results show the change in TVol (ΔTVol) (left panel) and the fractional change in T₁ (ΔT₁) (right panel) for each treatment on day 5, where **p < 0.01, ***p < 0.001 as shown. The ROC plots 1-specificity versus sensitivity for tumours treated with everolimus only and has an AUC = 0.84; the dashed line is the line of equivalence where the AUC = 0.5. B. C3H mice bearing RIF-1 tumours were treated with patupilone (3, 5 or 6 mg/kg i.v. bolus once) or vehicle and TVol and T₁ in tumours was measured on day 0 and at the endpoint day 7 (n = 8 per group). In some mice, T₁ could not always be determined and thus there were only n = 6 or 7 per group for analysis. Results show the ΔTVol (left panel) and the ΔT₁ (right panel) for each treatment on day 7 where ***p < 0.001 as shown. The ROC plots 1-specificity versus sensitivity for tumours treated with different doses of patupilone and has an AUC = 0.97; the dashed line is the line of equivalence where the AUC = 0.5.